Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Emergent Biosolutions Inc (NYSE: EBS) closed the day trading at $6.93 down -4.81% from the previous closing price of $7.28. In other words, the price has decreased by -$4.81 from its previous closing price. On the day, 0.68 million shares were traded. EBS stock price reached its highest trading level at $7.42 during the session, while it also had its lowest trading level at $6.9148.
Ratios:
For a better understanding of EBS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.98. For the most recent quarter (mrq), Quick Ratio is recorded 3.51 and its Current Ratio is at 6.32. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.21.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 23 ’25 when Katkin Keith sold 7,844 shares for $6.30 per share. The transaction valued at 49,417 led to the insider holds 86,431 shares of the business.
KEITH KATKIN bought 7,844 shares of EBS for $49,409 on May 23 ’25. On May 13 ’25, another insider, PAPA JOSEPH C, who serves as the President and CEO of the company, bought 60,000 shares for $5.83 each. As a result, the insider paid 349,800 and bolstered with 342,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 376145152 and an Enterprise Value of 869892544. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 0.68. Its current Enterprise Value per Revenue stands at 0.901 whereas that against EBITDA is 14.076.
Stock Price History:
The Beta on a monthly basis for EBS is 1.99, which has changed by -0.39528793 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $15.10, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 6.45%, while the 200-Day Moving Average is calculated to be -9.92%.
Shares Statistics:
Over the past 3-months, EBS traded about 1.29M shares per day on average, while over the past 10 days, EBS traded about 1066980 shares per day. A total of 54.50M shares are outstanding, with a floating share count of 51.92M. Insiders hold about 4.34% of the company’s shares, while institutions hold 66.30% stake in the company. Shares short for EBS as of 1749772800 were 7991534 with a Short Ratio of 7.76, compared to 1747267200 on 7911368. Therefore, it implies a Short% of Shares Outstanding of 7991534 and a Short% of Float of 14.87.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Emergent Biosolutions Inc (EBS) is currently being evaluated by a team of 2.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.26, with high estimates of $0.24 and low estimates of -$0.76.
Analysts are recommending an EPS of between $0.75 and $0.68 for the fiscal current year, implying an average EPS of $0.71. EPS for the following year is -$1.32, with 1.0 analysts recommending between -$1.32 and -$1.32.
Revenue Estimates
2 analysts predict $148.55M in revenue for the current quarter. It ranges from a high estimate of $192.1M to a low estimate of $105M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $254.7MFor the next quarter, 2 analysts are estimating revenue of $212.55M. There is a high estimate of $225M for the next quarter, whereas the lowest estimate is $200.1M.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $837.5M, while the lowest revenue estimate was $800.2M, resulting in an average revenue estimate of $815.34M. In the same quarter a year ago, actual revenue was $1.04BBased on 2 analysts’ estimates, the company’s revenue will be $951.08M in the next fiscal year. The high estimate is $1.2B and the low estimate is $707.15M.
